GILDGilead Sciences
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−1% a year). The price demands less than its three-year revenue growth of 4% a year, expectations look modest.
In its normal range: P/E 18.9 vs a 16.4 median over 37 quarters (+15% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What GILD's price assumes
Today's price asks for −1.3% free cash flow growth a year; over the last three years Gilead Sciences delivered 13%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 8.4%
Free cash flow yield · Drug Manufacturers - General median 5.7%
- Growth the price implies
- −1.3%
Growth the price implies · The price pays for −1.3% free cash flow growth a year for a decade; the business has delivered +13% a year over the last three.
- Price / book
- 13.0
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 13.0
- EV / EBIToperating margin −8.2%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 5.80
- Free cash flow, trailing twelve months
- $12.9B
- Market capitalisation
- $153.7B
- 3-year revenue growth
- +3.6%
- 3-year free cash flow growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, General
The closest names by size in the same industry